FDA grants fast track designation to Arena Pharmaceuticals' APD418 for development in decompensated heart failure patients

Arena Pharmaceuticals

16 January 2020 - Arena Pharmaceuticals today announced that the U.S. FDA granted fast track designation for APD418, a β3-adrenergic receptor antagonist and cardiac myotrope, in development for the treatment of decompensated heart failure.

APD418 is a first-in-class β3-adrenergic receptor antagonist and cardiac myotrope for decompensated heart failure. APD418 is a selective antagonist designed to improve cardiac contractility with minimal effect on heart rate, blood pressure and myocardial oxygen consumption, thus potentially avoiding adverse events associated with current inotrope therapies.

Read Arena Pharmaceuticals press release

Michael Wonder

Posted by:

Michael Wonder

Posted in:

Medicine , US , Fast track